New Liver Disease Drug Could Cut Itching and Fatigue
A phase 2b trial shows that volixibat may help patients manage symptoms of primary sclerosing cholangitis.
Updated on Oct. 15, 2026 in Diseases — General
Live Poll
Should medical research prioritize treating specific symptoms like chronic itching over other clinical outcomes?
The VISTAS phase 2b trial found that the investigational drug volixibat significantly improved pruritus, sleep quality, and fatigue in patients with primary sclerosing cholangitis. These preliminary findings offer a potential new therapeutic avenue for a condition that currently lacks any approved pharmacologic treatments.
Why it matters
Primary sclerosing cholangitis is a chronic liver disease that currently has no approved pharmacologic therapies to manage its debilitating symptoms. This trial provides a first look at a treatment that could potentially address the intense itching and fatigue that significantly impact quality of life for those living with the disease.
In a 28-week Phase 2b randomized trial of 111 patients, researchers found that volixibat significantly reduced pruritus and sleep disturbance compared to a placebo. While bile acid levels decreased significantly, the study noted that 93.5% of patients in the treatment group reported adverse events.
The players
VISTAS trial
A phase 2b study assessing the efficacy and safety of volixibat in patients with primary sclerosing cholangitis.
The details
Volixibat acts by inhibiting bile acid transport, a mechanism intended to reduce the accumulation of bile acids that contribute to the chronic itching characteristic of this liver condition. During the 28-week study, researchers observed that pruritus began to decline as early as two weeks after starting the twice-daily 20 mg regimen, reaching a peak reduction by weeks 4 to 5. While the results are encouraging, the trial also reported common treatment-emergent side effects including diarrhea, reported by 40.3% of the treatment arm, along with abdominal pain, nausea, and vitamin D deficiency.
Timeline
Pruritus began to decline after 2 weeks of treatment.
Maximum pruritus reduction occurred between 4 and 5 weeks.
The VISTAS trial concluded after 28 weeks.
Health Landscape
The treatment of primary sclerosing cholangitis has historically relied on supportive care due to the total absence of FDA-approved pharmacologic therapies. This trial represents a major shift toward targeted symptom management in a condition where options for patients remain severely limited.
For patients living with primary sclerosing cholangitis, these findings highlight a potential future option for managing persistent itching and sleep-related symptoms. Because these results are preliminary, anyone interested in these developments should discuss them with their physician.
The takeaway
Volixibat shows promise in reducing the bile acid levels and symptoms associated with primary sclerosing cholangitis. Patients should continue to monitor their current symptom management strategies and consult with a specialist regarding future enrollment in clinical trials.
Further reading
For more on evolving research in this area, visit Diseases — General.
Source note: This article includes information reported by Healio.
Live Poll
Should medical research prioritize treating specific symptoms like chronic itching over other clinical outcomes?
